(2nd LD) SK Biopharmaceuticals soars on market debut, largest IPO of the year
(ATTN: RECASTS first 3 paras with updated info)
By Chung Joo-won
SEOUL, July 2 (Yonhap) -- SK Biopharmaceuticals Co. Ltd., the largest initial public offering (IPO) of the year so far, made a strong market debut Thursday, finishing at more than two times the IPO price.
The unit of South Korean conglomerate SK Group closed at 127,000 won (US$105), rising by a daily permissible limit of 30 percent, sharply up from the IPO price of 49,000 won.
The company's market cap stood at 9.95 trillion won, the 27th most-valued stock on the main bourse.
Samsung Securities analyst Yang Il-woo put the valuation of the company at 7.8 trillion won.
"Bio stocks are likely to fare better amid the prolonged impact from the COVID-19 pandemic, with major economies pushing various monetary easing and stimulus packages to keep the low-interest environment," he added.
The drugmaker raised some 960 billion won via IPO, the largest stock offering of the year. The IPO offering also marks the highest since the 1 trillion-won IPO deal by Celltrion Healthcare in 2017.
Prior to its IPO, investors rushed for SK Biopharmaceuticals for its growth potential amid the coronavirus pandemic. They chipped in 31 trillion won in deposits to buy its stocks, the largest in the country's IPO history.
"SK Biopharmaceuticals will accelerate into the global pharmaceutical company through the IPO," CEO Cho Jeong-woo said.
The company, which specializes in the research and development of treatments for disorders, currently has two indigenous drugs with the U.S. Food and Drug Administration (FDA) approvals.
It was the first South Korean company to independently develop an anti-epileptic drug, Cenobamate, and to receive a green light from the FDA.
Its novel sleep disorder drug, named solriamfetol, is also available in both the United States and Germany.
The drugmaker was spun off in 2011 from the life science unit of SK Group that holds a 75 percent stake.
jwc@yna.co.kr
khj@yna.co.kr
(END)
-
(News Focus) Samsung's Lee expected to solidify leadership, step up biz activities after receiving pardon
-
S. Korea expresses deep regret over Japanese PM's offering to war shrine
-
(LEAD) Yoon pledges to improve ties with Japan, offers economic aid in exchange for N.K. denuclearization
-
(LEAD) Bill Gates calls for S. Korea to play leading role in global health cooperation
-
Jungkook, first runner of BTS' photo album project
-
(2nd LD) Samsung heir Lee granted special presidential pardon
-
(News Focus) Samsung's Lee expected to solidify leadership, step up biz activities after receiving pardon
-
(LEAD) Yoon pledges to improve ties with Japan, offers economic aid in exchange for N.K. denuclearization
-
Today in Korean history
-
Ex-ruling party chair takes swipe at Yoon amid legal action over leadership switch
-
(LEAD) N. Korea fires two cruise missiles toward Yellow Sea: S. Korean official
-
Preorders for BLACKPINK's second LP surpass 1.5 mln copies
-
Busan mayor proposes allowing alternative military services for BTS
-
U.S. will maintain sanctions until N. Korea changes behavior: State Dept.
-
(LEAD) New COVID-19 cases near 180,000; imported cases hit record high